Welcome to our dedicated page for Calidi Biotherapeutics SEC filings (Ticker: CLDI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, cash-burn tables, and stem-cell delivery jargon make Calidi Biotherapeutics’ SEC disclosures tough to navigate. Missing a single 8-K data point on a Phase 1 read-out could mean mispricing the stock. Stock Titan’s AI-driven platform removes that risk by translating every Calidi Biotherapeutics SEC filing into clear, actionable language—while the document is still hitting EDGAR.
Whether you need a Calidi Biotherapeutics quarterly earnings report 10-Q filing to track R&D spend, or a Calidi Biotherapeutics annual report 10-K simplified to understand liquidity runway, you’ll find it here—fully annotated. Our engine delivers:
- Real-time alerts for Calidi Biotherapeutics Form 4 insider transactions real-time so you can spot executive conviction.
- Concise explanations that make Calidi Biotherapeutics 8-K material events explained readable in minutes.
- Side-by-side charts that turn Calidi Biotherapeutics earnings report filing analysis into trend insights.
Trying to decode stock grants buried in the DEF 14A? Our summary of the Calidi Biotherapeutics proxy statement executive compensation highlights option pricing and performance hurdles. Need context on a sudden share sale? The platform tags each Calidi Biotherapeutics executive stock transactions Form 4 against trial timelines for true signal versus noise.
From “understanding Calidi Biotherapeutics SEC documents with AI” to tracking every Calidi Biotherapeutics insider trading Form 4 transactions, Stock Titan provides comprehensive coverage, updated the second the filing posts. Complex biotech filings, explained simply—so you can focus on decisions, not document hunts.
Calidi Biotherapeutics (CLDI) filed its Q3 2025 report showing continued operating losses and a going concern warning. The company reported a Q3 net loss of
Liquidity remains tight. Cash was
The company effected a 1‑for‑12 reverse stock split effective August 4, 2025; trading began on a split‑adjusted basis on August 5, 2025. As of November 10, 2025, 7,167,721 common shares were outstanding, excluding 150,000 non‑voting shares held in escrow. Year‑to‑date, financing activities provided
Calidi Biotherapeutics (CLDI) filed an 8-K stating it furnished a press release with certain financial results for the third quarter ended September 30, 2025 and recent corporate developments. The release is attached as Exhibit 99.1 and referenced under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
The company notes the information in these items, including Exhibit 99.1, is furnished, not filed under the Exchange Act’s Section 18 and is not incorporated by reference into Securities Act or Exchange Act filings except by specific reference.
Calidi Biotherapeutics (CLDI) announced it presented new data on its first RedTail platform candidate, CLD-401, at the Society for Immunotherapy of Cancer Annual Meeting. The company furnished a webinar presentation and a scientific poster as Exhibits 99.1 and 99.2, and a related press release as Exhibit 99.3. The disclosure is provided under Item 7.01 (Regulation FD) and is not deemed “filed” under the Exchange Act.
Calidi Biotherapeutics (CLDI) divested its entire stake in Nova Cell. On October 27, 2025, the company entered into a Stock Repurchase Agreement and a Material Purchase Agreement with Nova Cell. Calidi sold and transferred 22,500,000 Nova Cell common shares, representing 75% of Nova Cell and 100% of Calidi’s ownership, for a purchase price of $6,000,000.
The price will be satisfied by cancellation of indebtedness of $1,214,864 and deferred consideration of $4,785,136 payable after closing. The agreement also provides for an ongoing royalty at a fixed percentage of Covered Gross Revenue tied to materials listed in the MPA, payable quarterly within 30 days after each quarter-end. Following closing, Nova Cell is no longer a Calidi subsidiary. Calidi estimates $0.5 million per year in general and administrative expense reductions.
The MPA supersedes a July 28, 2024 IP Assignment, transfers specified materials (with a prohibition on uses relating to oncolytic viruses), and allows Calidi to retain stocks of certain cell lines for its own use.
Calidi Biotherapeutics (CLDI) furnished an investor update and announced a new scientific advisory board. The company made an updated corporate presentation available on its website, furnished as Exhibit 99.1 under a Regulation FD Item 7.01 disclosure.
Separately, Calidi issued a press release on October 22, 2025 (Exhibit 99.2) announcing the formation of a scientific advisory board to support development of its RedTail platform and advance CLD-401 into the clinic. The furnished materials are not deemed filed for liability purposes under the Exchange Act.
Calidi Biotherapeutics insider grant: Chief Executive Officer Eric E. Poma was granted 10,000 incentive stock options under the issuer's 2023 Equity Incentive Plan on 09/03/2025 at an exercise price of $1.58, equal to the closing price that day. The options are exercisable beginning on the grant date and expire on 09/03/2035. Vesting is 25% after one year and the remaining 75% vests in 1/36th monthly installments thereafter, conditioned on continued service. The grant was made pursuant to Rule 16b-3 exemption.
Calidi Biotherapeutics insider grant: On 09/03/2025 the company's Chief Scientific Officer, Antonio Fernandez Santidrian, received a grant of 35,000 incentive stock options under the Issuer's 2023 Equity Incentive Plan.
The options have an exercise price of $1.58, which equals the common stock closing price on the grant date. Twenty-five percent of the options vest after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. The options are exercisable beginning 09/03/2025 and expire 09/03/2035. The grant was made pursuant to Rule 16b-3.
Calidi Biotherapeutics, Inc. (CLDI) reported that Andrew C. Jackson, the companys Chief Financial Officer, was granted 30,000 incentive stock options on 09/03/2025 under the 2023 Equity Incentive Plan. The options have an exercise price of $1.58, which the filing states equals the closing price on the grant date. Twenty-five percent of the options vest after one year, with the remaining 75% vesting in equal monthly installments over the following three years. The options are exercisable beginning 09/03/2025 and expire on 09/03/2035. The grant was reported as exempt under Rule 16b-3.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
